Tada, H <br/><br/>
Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.  [electronic resource] 

 -  European journal of cancer care  Mar 2008 
 - 120-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1365-2354 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2354.2007.00816.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Case-Control Studies<br/>Cisplatin--administration & dosage<br/>Cost-Benefit Analysis<br/>Deoxycytidine--administration & dosage<br/>Docetaxel<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Taxoids--administration & dosage<br/>Treatment Outcome<br/>Vinblastine--administration & dosage<br/>Vinorelbine<br/>Gemcitabine